Department of General Intensive Care, University Hospital of Liege, Domaine universitaire de Liège, Liege, Belgium.
Crit Care Med. 2012 Aug;40(8):2304-9. doi: 10.1097/CCM.0b013e318251517a.
To test the usefulness of procalcitonin serum level for the reduction of antibiotic consumption in intensive care unit patients.
Single-center, prospective, randomized controlled study.
Five intensive care units from a tertiary teaching hospital.
All consecutive adult patients hospitalized for >48 hrs in the intensive care unit during a 9-month period.
Procalcitonin serum level was obtained for all consecutive patients suspected of developing infection either on admission or during intensive care unit stay. The use of antibiotics was more or less strongly discouraged or recommended according to the Muller classification. Patients were randomized into two groups: one using the procalcitonin results (procalcitonin group) and one being blinded to the procalcitonin results (control group). The primary end point was the reduction of antibiotic use expressed as a proportion of treatment days and of daily defined dose per 100 intensive care unit days using a procalcitonin-guided approach. Secondary end points included: a posteriori assessment of the accuracy of the infectious diagnosis when using procalcitonin in the intensive care unit and of the diagnostic concordance between the intensive care unit physician and the infectious-disease specialist.
There were 258 patients in the procalcitonin group and 251 patients in the control group. A significantly higher amount of withheld treatment was observed in the procalcitonin group of patients classified by the intensive care unit clinicians as having possible infection. This, however, did not result in a reduction of antibiotic consumption. The treatment days represented 62.6±34.4% and 57.7±34.4% of the intensive care unit stays in the procalcitonin and control groups, respectively (p=.11). According to the infectious-disease specialist, 33.8% of the cases in which no infection was confirmed, had a procalcitonin value>1µg/L and 14.9% of the cases with confirmed infection had procalcitonin levels<0.25 µg/L. The ability of procalcitonin to differentiate between certain or probable infection and possible or no infection, upon initiation of antibiotic treatment was low, as confirmed by the receiving operating curve analysis (area under the curve=0.69). Finally, procalcitonin did not help improve concordance between the diagnostic confidence of the infectious-disease specialist and the ICU physician.
Procalcitonin measuring for the initiation of antimicrobials did not appear to be helpful in a strategy aiming at decreasing the antibiotic consumption in intensive care unit patients.
检验降钙素原血清水平对降低重症监护病房患者抗生素使用量的作用。
单中心前瞻性随机对照研究。
一所三级教学医院的 5 个重症监护病房。
9 个月期间,所有在重症监护病房住院超过 48 小时的连续成年患者。
对所有疑似发生感染的连续患者,在入院时或入住重症监护病房期间,检测降钙素原血清水平。根据 Muller 分类,强烈建议或不建议使用抗生素。患者随机分为两组:一组使用降钙素原结果(降钙素原组),另一组对降钙素原结果设盲(对照组)。主要终点是抗生素使用的减少,用抗生素治疗天数和每 100 个重症监护病房日的每日定义剂量表示,采用降钙素原指导的方法。次要终点包括:在重症监护病房使用降钙素原时,对感染诊断的准确性进行回顾性评估,以及重症监护病房医生和传染病专家之间的诊断一致性。
降钙素原组有 258 例患者,对照组有 251 例患者。重症监护病房医生分类为可能感染的患者中,观察到明显更多的治疗被取消。然而,这并没有导致抗生素使用量的减少。降钙素原组和对照组的治疗天数分别占重症监护病房入住天数的 62.6%±34.4%和 57.7%±34.4%(p=.11)。根据传染病专家的意见,未确诊感染的病例中,有 33.8%的降钙素原值>1µg/L,确诊感染的病例中有 14.9%的降钙素原水平<0.25 µg/L。降钙素原区分起始抗生素治疗时的确定或可能感染与可能或无感染的能力较低,正如接收者操作曲线分析所证实(曲线下面积=0.69)。最后,降钙素原并没有帮助提高传染病专家和重症监护病房医生诊断信心的一致性。
降钙素原检测用于启动抗生素治疗似乎并不能帮助降低重症监护病房患者的抗生素使用量。